Untapped Markets: Jefferies Believes Eli Lilly's Global GLP-1 Potential is Still Underestimated
Reading Time: 2 minutes
More Optimistic Price Target: Jefferies raises the target price for Eli Lilly to $1.700 and reaffirms the buy recommendation. Growth Lever Abroad: International markets could generate around half of the global GLP-1 volume in the long term. Digital Sales Initiative: Partnership with Hims & Hers opens direct access for self-pay patients starting at $149 and secures patent protection against unregulated copies. While Wall Street primarily gauges the demand for GLP-1 products based on the US healthcare market, there is a...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
